Men Die of Melanoma at Twice the Rate of Women. Most of That Gap Is a Looking Problem.

A gap that is not subtle

Sex differences show up in most cancers. Few of them look like this one.

Pooled US surveillance data put melanoma incidence at roughly 27.4 per 100,000 in men against 16.8 in women, and mortality at about 3.9 per 100,000 against 1.6. The American Cancer Society's projection for 2026 runs in the same direction in raw counts: around 65,400 new melanomas in men and 46,600 in women, with about 5,500 male deaths against 3,010 female. Whichever denominator you prefer, a man is meaningfully more likely to get melanoma and considerably more likely to die of it.

The age curve is the part almost nobody knows. Up to about age 50, women actually carry roughly twice the melanoma incidence of men — a fact that maps neatly onto tanning-bed history and leg exposure. Then the curves cross. By 60, men have twice the incidence of women; by 70, about three times. The disease that reads as a young woman's risk in her twenties becomes an older man's risk in his sixties, and the public health messaging has never really caught up with the handoff.

So the headline is real. The interesting question is what is driving it, because the answer determines whether anything can be done.

The share of it that really is biology

Start with the part that is not behavioral, because pretending otherwise would be dishonest.

Women keep a survival advantage even after adjusting for stage at diagnosis — on the order of 38% in pooled analyses. That is not a detection artifact. Adjusting for stage means you have already accounted for how early the tumor was caught; something about male tumors, male immune response, or both is genuinely less favorable. Whether that is hormonal, immunologic, or something else is still unsettled.

Then there is subtype, and this is where biology and detection become impossible to separate. Nodular melanoma grows vertically and fast. In a Victorian cancer registry analysis covering 5,775 invasive melanomas, nodular tumors made up about 14% of cases but were responsible for roughly 43% of melanoma deaths. Superficial spreading melanoma — the flat, irregular, slowly widening kind — was 56% of cases and 30% of deaths. Median thickness at diagnosis tells the story plainly: 2.6 mm for nodular versus 0.6 mm for superficial spreading. Men skew toward the nodular end of that distribution.

Here is the trap. The ABCDE rule — asymmetry, border irregularity, color variation, diameter over 6 mm, evolution — was built around the superficial spreading pattern. A nodular melanoma is often symmetric, evenly bordered, uniformly colored, and small. It can fail four of the five criteria and still kill you within the year. The clinical shorthand that catches it is EFG: elevated, firm, growing. If a bump is raised, feels solid rather than soft, and has changed in the past month or two, that combination outranks every letter of ABCDE. Our ABCDE Mole Check walkthrough carries that caveat, and it is the single most useful thing on the page for a man over 50.

You cannot examine a back you cannot see

Now the part that is not biology at all.

Men's melanomas concentrate on the trunk — the back above all — plus the head and neck. Women's concentrate on the legs. That distribution alone predicts most of what follows, because one of those regions is visible in a bathroom mirror during an ordinary morning and the other is not.

The detection data make it concrete. A prospective study of 471 newly diagnosed melanoma patients at Memorial Sloan Kettering found that 57% of lesions were found by the patient — but broken down by sex, women self-detected 69% of the time and men only 47%. Physicians found 16%. Spouses found 11%, and within that group, detection by wives was 7.5 times more common than detection by husbands. A later Spanish series of 783 patients confirmed the anatomy: men had significantly more melanomas in locations that are not easily visible, and lesions first noticed by a dermatologist had better outcomes than self-detected ones, with 80% of those dermatologist-found lesions turning up as incidental discoveries during a visit for something else entirely.

Read those two findings together and the mortality gap starts to look less like a disease and more like a logistics failure. The tumor lands on a surface the patient never inspects. The household member most statistically likely to notice it is, in the aggregate, not looking either. And the clinician who would catch it early is only in the picture if the man happens to be in a dermatology chair for something unrelated. Middle-aged men are the demographic least likely to be in that chair.

The fix is unglamorous and almost free: one other person, once a season, with a phone. A dated set of back photographs is worth more than any amount of self-inspection, because melanoma detection is fundamentally a comparison task — you are not looking for an ugly spot, you are looking for a spot that changed. That is what a tracker like Mole Map exists to hold: a marker for every spot you are watching, with dated observations underneath it, so the comparison is against a record instead of a memory.

What the screening evidence actually supports

This is where a lot of skin cancer content overclaims, and it is worth being precise, because the overclaim is exactly what makes skeptical readers tune out.

In 2023 the US Preventive Services Task Force reaffirmed an I statement on skin cancer screening: for asymptomatic adolescents and adults, the evidence is insufficient to weigh the benefits and harms of a routine visual skin exam by a clinician. Three nonrandomized analyses found no melanoma mortality benefit at the population level over four to ten years of follow-up. Anyone telling you that an annual full-body check is a proven life-saver for the general population is going beyond what the data show, and the Task Force said so twice — in 2016 and again in 2023.

But read the boundary of that statement carefully, because it is doing real work. The I statement covers asymptomatic people with no family history. It explicitly does not apply to someone with a family history of skin cancer, or to anyone with a sign or symptom — an irregular mole, or any change in the size, shape, or color of a growth. Those people are not being screened. They are being evaluated, and the evidence base for evaluating a changing lesion is not in question. Confusing the two is the most common misreading of the recommendation.

What does have supporting evidence is sharpening the comparison. The ugly duckling sign — the mole that simply does not belong with the rest of your moles — was tested against lesion-by-lesion inspection using 2,089 clinical images read blind by nine dermatologists. Every melanoma in the set was flagged as an ugly duckling by all nine readers. Comparative analysis ran a specificity of 0.96 against 0.88 for lesion-focused analysis, and combining the two cut the number of lesions considered for biopsy by a factor of 6.9. The lesson for a non-specialist is direct: do not audit each spot against a checklist. Scan the whole field and find the outlier. That is also why a risk tier is worth establishing once — the Skin Cancer Risk Tier screener sorts phototype, burn history, mole count and family history into a surveillance cadence, and family history in particular moves you outside the I statement entirely.

The exposure story most men have backwards

There is a belief, common among men who work outdoors, that a permanent tan is a form of protection and that the real danger belongs to pale office workers who burn on holiday. The evidence is messier than either camp wants.

Melanoma risk tracks most strongly with intermittent, intense, burn-heavy exposure — the shirtless Saturday, the sunburn at 14, the week in the sun after eleven months indoors. Chronic occupational exposure has produced conflicting results across studies, with the WHO's own pooled estimate landing on a modest increase and several systematic reviews finding no clear elevation for outdoor work specifically. Some analyses have even found a suggestive inverse relationship at higher latitudes. That does not make outdoor work safe. It makes it a different exposure with a different consequence profile.

Because cumulative daily sun is unambiguously the driver of actinic damage — the rough, scaly, sandpapery patches that show up on scalps, ears, foreheads and forearms after decades of it. Those are precancerous, they behave nothing like melanoma, and they are managed on a completely different clock; ↗the actinic keratosis pathway lays out that escalation. Scalp is the site men underestimate most, particularly once hair thins, and ↗the question of how much sunscreen a bald scalp actually needs has a specific answer that most people undershoot badly.

Which brings up the practical failure that undoes everything else: men skip sunscreen at higher rates, and the usual reason given is texture. A sticky white film under a work shirt is a product people quietly abandon by week two. The category has solved this — a zinc-led sport formula like ↗Blue Lizard Sport Mineral SPF 50+ or ↗Coppertone Sport Mineral SPF 50 is built for sweat and water rather than for a bathroom mirror, and an oil-free option like ↗Jack Black Oil-Free Sun Guard SPF 45 exists precisely for the man who tried a heavy face sunscreen once and never repeated the experience. For torso and shoulders on a long day outside, a fluid high-SPF body formula such as ↗La Roche-Posay Anthelios Melt-In Milk SPF 100 covers a lot of surface area without a fight. If shine and breakouts are the specific objection, ↗our ranking for oily skin narrows the field faster than a shelf does, and ↗zinc oxide is worth understanding on its own terms before you decide mineral filters are all chalk.

A protocol that takes fifteen minutes a season

None of this requires a routine, a cabinet, or a subscription. It requires four things done on a calendar.

First: recruit one person. Partner, sibling, close friend — someone who will spend five minutes with a phone camera and photograph your back, shoulders, the back of your neck and the top of your scalp under decent light. Same light, same angles, four times a year. Structured partner-assisted skin examination has been the subject of multiple randomized trials in melanoma survivors precisely because trained pairs outperform lone patients on knowledge, skill and accuracy. You do not need the formal curriculum. You need a second set of eyes and a dated photograph.

Second: scan for the outlier, not the checklist. Look at the whole field and ask which spot is not like the others. That comparative habit is what the ugly duckling data supports, and it is faster than grading every mole you own.

Third: learn EFG alongside ABCDE, and give it priority for anything raised. Elevated, firm, growing over weeks rather than years — that is the pattern that produces the thick tumors, and it is the pattern the standard mnemonic handles worst. Anything that bleeds without being knocked, itches persistently, or refuses to heal over a month belongs in front of a clinician regardless of how it scores on any letter.

Fourth: extend the sweep past skin. Melanoma also arises under nails and on soles, where it is missed for far longer; a dark longitudinal band under a fingernail or toenail that widens, or that smudges pigment into the surrounding skin fold, is not a bruise or a fungal infection, and ↗the reasons subungual melanoma is diagnosed so late are worth ten seconds of reading before you dismiss a dark streak.

The uncomfortable conclusion of the detection literature is that the highest-leverage intervention in men's skin health is not a product at all. It is a recurring appointment with another human being who is willing to look at a part of your body you have never seen. Everything else in this article is downstream of whether that appointment exists.